Helixgate https://validator.w3.org/feed/docs/rss2.html Home Opinion: Dr. Glaucomflecken wants the corporatization of medicine to be national news Biotech’s new company model; The super poop behind a startup launch; and more New Hepta blood test could predict GLP-1 response Spain readies for evacuations as a hantavirus-hit cruise ship heads for the Canary Islands STAT+: Roche to buy PathAI for $750 million STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug Trump signs off on plan to oust embattled FDA Commissioner Marty Makary: report FDA Commissioner Makary to be fired, WSJ reports Daiichi Sankyo posts ‘extraordinary loss’ of nearly $1B How Digital Orchestration Is Redefining Regulatory Infrastructure for Cell and Gene Therapy Remembering J. Craig Venter, PhD Opinion: I’m fighting misinformation online. False hantavirus claims follow a now-familiar playbook Former FDA leaders, pharma speak out on mifepristone Trump plans to fire FDA chief Marty Makary: report FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering Macrophages Use Cell Volume Changes to Sense Danger and Amplify Inflammation Fraudulent citations, blamed on AI hallucinations, are becoming more common in research papers Astellas touts data from early test of stem cell-derived eye therapy From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies ASGCT CEO David Barrett Previews the Upcoming Conference in Boston ParcelBio Unveils Programmable mRNA Platform Backed by $13M Financing Rewriting the Oncology Playbook ASGCT Honors Mohamed Abou‑el‑Enein as Outstanding New Investigator Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy The aging scientific workforce collides with rising fabricating citations in medical journals Natalie Holles’ next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech Opinion: STAT+: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting Odyssey raises more than $300M as biotech goes public in IPO Odyssey, on second try, snags $279M in an IPO G-Link CAR-T Delivery Platform Showcased at ASGCT FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended Sarepta tumbles as its gene therapy sales decline further Key takeaways from WHO briefing on hantavirus cruise ship outbreak Human Antibodies Identified That Have Potential To Prevent and Treat Measles Virus Digital PCR Playbook: Applications and Challenges Across Research and Clinical Labs Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and more Science is becoming less disruptive. Is an aging workforce to blame? FDA pilots AI-informed one-day facility inspections Amazon adds Ozempic pill to same-day prescription drug kiosks Official leading CDC’s cruise ship program retires EnGene’s shares crash on updated pivotal bladder cancer data ‘Pharma, not really’: Top young AI talent shuns careers at big drugmakers Angelini to buy Catalyst in $4B play for rare neuro drugs FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit Lilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site STAT+: More political interference at the FDA? Angelini inks $4.1B Catalyst buy to enter US rare disease market Gilead sets blockbuster bar for Yeztugo’s first full year on the market